Enhabit, Inc (EHAB)

Over the last 12 months, Enhabit's stock price increased by 17.28%, though it experienced a 4.98% decrease in the past month as of January 2, 2026. Between December 16, 2024, and December 12, 2025, the share price increased by 13.62%, from $8.52 to $9.68 per share. A strategic review exploring a potential sale or merger concluded with Enhabit remaining independent due to macroeconomic challenges. The company also faced a proxy contest with AREX Capital Management, LP, leading up to its 2024 annual meeting, with the board acknowledging that financial results and stock performance had not met expectations since the spin-off.

Demand for Enhabit's hospice services exhibits some seasonality, with holiday times tending to be unpredictable and potentially leading to fluctuations in hospice length of stay.

Enhabit, Inc. is a national provider of home-based healthcare services, operating within the Healthcare sector. The company delivers personalized clinical and non-clinical services that support patients in their homes, aiding recovery, managing chronic conditions, and providing end-of-life care. Enhabit's service portfolio includes Home Health services such as skilled nursing, therapies, personal care, patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, and specialized programs for chronic diseases. Hospice services focus on pain and symptom management, counseling, social worker visits, and bereavement counseling. Enhabit uses proprietary care-management technology to streamline workflows, improve care coordination, and reduce hospital readmissions.

Enhabit operates across 34 states in the U.S., serving both urban and rural markets. As of September 30, 2025, the company had 247 home health locations and 115 hospice locations, achieved through organic growth and strategic acquisitions.

Enhabit's brand reputation has been influenced by its financial and stock performance since its spin-off, the strategic review, and a proxy fight with AREX Capital Management, LP. Despite these challenges, Enhabit has emphasized its commitment to quality patient care. In 2023, the company reported a 30-day hospital readmission rate that was 20.5% lower than the 2022 national average, and its Quality of Patient Care star rating was 16.7% better than the national average. Enhabit also performed 52.3% better than the national average in hospice visits by a registered nurse or medical social worker in two of the last three days of a patient's life.

Enhabit, Inc.'s ownership is a mix of institutional, insider, and public investors. Institutional investors hold a significant portion, ranging from approximately 42.10% to 98.55% of the company's stock. Insiders own between 3.41% and 3.98%, while public companies and individual investors hold approximately 14.11% to 25.25%. Major institutional shareholders include Deerfield Management Company, L.P., 8 Knots Management, LLC, BlackRock, Inc., Vanguard Group Inc, UBS Group AG, AREX Capital Management, LP, JANA Partners Management, LP, Dimensional Fund Advisors Lp, Systematic Financial Management Lp, and Paradice Investment Management LLC. Barbara Ann Jacobsmeyer, the CEO, is the largest individual shareholder, owning 1.09% of the company.